Abiopharma

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

New Form 8-K - INTEGRA LIFESCIENCES HOLDINGS CORP Filed: 2025-06-09 AccNo: 0000917520-25-000060 Size: 353 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-06-09 AccNo: 0001575872-25-000395 Size: 97 KB

New Form 8-K - Lipocine Inc. Filed: 2025-06-09 AccNo: 0001641172-25-014224 Size: 240 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Tvardi Therapeutics, Inc. Filed: 2025-06-09 AccNo: 0001104659-25-057524 Size: 7 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Hoth Therapeutics, Inc. Filed: 2025-06-09 AccNo: 0001213900-25-052295 Size: 17 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 4 - RenovoRx, Inc. Filed: 2025-06-09 AccNo: 0001641172-25-014212 Size: 5 KB

New Form 424B4 - AYTU BIOPHARMA, INC Filed: 2025-06-09 AccNo: 0001437749-25-019761 Size: 1 MB

Portage Biotech and Compedica Stock-for-Stock Exchange

Alnylam Receives European Commission Approval forAMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

New Form EFFECT - Akso Health Group Filed: 2025-06-06 AccNo: 9999999995-25-001852 Size: 2 KB

New Form EFFECT - Safety Shot, Inc. Filed: 2025-06-06 AccNo: 9999999995-25-001860 Size: 1 KB

New Form EFFECT - Entera Bio Ltd. Filed: 2025-06-06 AccNo: 9999999995-25-001864 Size: 1 KB

New Form EFFECT - 23andMe Holding Co. Filed: 2025-06-06 AccNo: 9999999995-25-001850 Size: 2 KB